neuroprotective agents

Summary

Summary: Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids.

Top Publications

  1. ncbi Mechanisms, challenges and opportunities in stroke
    Eng H Lo
    Neuroprotection Research Laboratory, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA
    Nat Rev Neurosci 4:399-415. 2003
  2. ncbi Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease
    D C Wu
    Department of Neurology, Columbia University, New York, New York 10032, USA
    J Neurosci 22:1763-71. 2002
  3. ncbi 1,026 experimental treatments in acute stroke
    Victoria E O'Collins
    Neuroscience Lab, Department of Medicine, University of Melbourne, Austin Health, Heidelberg, VIC 3084, Australia
    Ann Neurol 59:467-77. 2006
  4. pmc VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia
    Yunjuan Sun
    Buck Institute for Age Research, Novato, California 94945, USA
    J Clin Invest 111:1843-51. 2003
  5. pmc Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury
    Kazuaki Nishijima
    R and D Consultants, Barnet, Herts, UK
    Am J Pathol 171:53-67. 2007
  6. ncbi Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention
    Bin Liu
    Neuropharmacology Section, Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA
    J Pharmacol Exp Ther 304:1-7. 2003
  7. ncbi Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia
    T Tikka
    A. I. Virtanen Institute for Molecular Sciences, University of Kuopio, FIN-70211 Kuopio, Finland
    J Neurosci 21:2580-8. 2001
  8. ncbi Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult
    Andrew D Kraft
    School of Pharmacy, University of Wisconsin, Madison, Wisconsin 53705 2222, USA
    J Neurosci 24:1101-12. 2004
  9. pmc Neuroprotection for ischemic stroke: past, present and future
    Myron D Ginsberg
    Department of Neurology D4 5, University of Miami Miller School of Medicine, Miami, FL 33101, USA
    Neuropharmacology 55:363-89. 2008
  10. pmc ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease
    Pamela Maher
    Department of Cellular Neurobiology, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA
    Hum Mol Genet 20:261-70. 2011

Detail Information

Publications407 found, 100 shown here

  1. ncbi Mechanisms, challenges and opportunities in stroke
    Eng H Lo
    Neuroprotection Research Laboratory, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA
    Nat Rev Neurosci 4:399-415. 2003
  2. ncbi Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease
    D C Wu
    Department of Neurology, Columbia University, New York, New York 10032, USA
    J Neurosci 22:1763-71. 2002
    ..This study demonstrates that microglial-related inflammatory events play a significant role in the MPTP neurotoxic process and suggests that minocycline may be a valuable neuroprotective agent for the treatment of PD...
  3. ncbi 1,026 experimental treatments in acute stroke
    Victoria E O'Collins
    Neuroscience Lab, Department of Medicine, University of Melbourne, Austin Health, Heidelberg, VIC 3084, Australia
    Ann Neurol 59:467-77. 2006
    ..Therefore, we endeavored to contrast experimental efficacy and scope of testing of drugs used clinically and those tested only experimentally...
  4. pmc VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia
    Yunjuan Sun
    Buck Institute for Age Research, Novato, California 94945, USA
    J Clin Invest 111:1843-51. 2003
    ..VEGF may, therefore, improve histological and functional outcome from stroke through multiple mechanisms...
  5. pmc Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury
    Kazuaki Nishijima
    R and D Consultants, Barnet, Herts, UK
    Am J Pathol 171:53-67. 2007
    ..These findings have implications for both neural pathologies and ocular vascular diseases, such as diabetic retinopathy and age-related macular degeneration...
  6. ncbi Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention
    Bin Liu
    Neuropharmacology Section, Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA
    J Pharmacol Exp Ther 304:1-7. 2003
    ..In addition, we also discuss novel approaches to potential therapeutic strategies...
  7. ncbi Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia
    T Tikka
    A. I. Virtanen Institute for Molecular Sciences, University of Kuopio, FIN-70211 Kuopio, Finland
    J Neurosci 21:2580-8. 2001
    ..These findings indicate that the proliferation and activation of microglia contributes to excitotoxicity, which is inhibited by minocycline, an antibiotic used in severe human infections...
  8. ncbi Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult
    Andrew D Kraft
    School of Pharmacy, University of Wisconsin, Madison, Wisconsin 53705 2222, USA
    J Neurosci 24:1101-12. 2004
    ..Strikingly, the change in neuronal gene expression after tBHQ treatment was dependent on Nrf2 activity in the astrocytes. This suggests that Nrf2-dependent genetic changes alter neuron-glia interactions resulting in neuroprotection...
  9. pmc Neuroprotection for ischemic stroke: past, present and future
    Myron D Ginsberg
    Department of Neurology D4 5, University of Miami Miller School of Medicine, Miami, FL 33101, USA
    Neuropharmacology 55:363-89. 2008
    ..This review presents a close survey of the most extensively evaluated neuroprotective agents and classes and considers both the strengths and weakness of the pre-clinical evidence as well as the ..
  10. pmc ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease
    Pamela Maher
    Department of Cellular Neurobiology, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA
    Hum Mol Genet 20:261-70. 2011
    ..Thus, fisetin, resveratrol and related compounds might be useful for the treatment of HD by virtue of their unique ability to activate ERK...
  11. pmc Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies
    David J Loane
    Department of Anesthesiology and Center for Shock, Trauma and Anesthesiology Research STAR, National Study Center for Trauma and Emergency Medical Systems, University of Maryland School of Medicine, Baltimore, MD, USA
    Trends Pharmacol Sci 31:596-604. 2010
    ..Here we critically review developing experimental neuroprotective strategies that show promise, and we propose criteria for improving the probability of successful clinical translation...
  12. pmc NADPH oxidases: novel therapeutic targets for neurodegenerative diseases
    Hui Ming Gao
    Neuropharmacology Section, Laboratory of Toxicology and Pharmacology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA
    Trends Pharmacol Sci 33:295-303. 2012
    ..Thus, proper modulation of NADPH oxidase activity might hold therapeutic potential for currently incurable neurodegenerative diseases...
  13. pmc Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress
    A L Siren
    Max Planck Institute for Experimental Medicine, Georg August University, 37075 Goettingen, Germany
    Proc Natl Acad Sci U S A 98:4044-9. 2001
    ..The neurotrophic actions suggest there may be longer-latency effects as well. Evaluation of EPO, a compound established as clinically safe, as neuroprotective therapy in acute brain injury is further supported...
  14. pmc Inflammatory mechanisms in ischemic stroke: therapeutic approaches
    Shaheen E Lakhan
    Global Neuroscience Initiative Foundation, Los Angeles, CA, USA
    J Transl Med 7:97. 2009
    ..However, recent studies showing that regulatory T cells are major cerebroprotective immunomodulators after stroke suggest that targeting the endogenous adaptive immune response may offer novel promising neuroprotectant therapies...
  15. ncbi Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
    Jeffrey D Rothstein
    Department of Neurology, Johns Hopkins University, Baltimore, Maryland 21287, USA
    Nature 433:73-7. 2005
    ..Thus these studies provide a class of potential neurotherapeutics that act to modulate the expression of glutamate neurotransmitter transporters via gene activation...
  16. pmc Interleukin-34 selectively enhances the neuroprotective effects of microglia to attenuate oligomeric amyloid-β neurotoxicity
    Tetsuya Mizuno
    Department of Neuroimmunology, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan
    Am J Pathol 179:2016-27. 2011
    ..These findings support the idea that enhancement of the neuroprotective property of microglia by IL-34 may be an effective approach against oAβ neurotoxicity in AD...
  17. pmc Heme oxygenase 1, beneficial role in permanent ischemic stroke and in Gingko biloba (EGb 761) neuroprotection
    Z A Shah
    Department of Medicinal and Biological Chemistry, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, OH 43614, USA
    Neuroscience 180:248-55. 2011
    ..Together, these results suggest that HO1 plays, at least in part, an important role in the neuroprotective mechanism of EGb 761 and in delayed ischemia. Targeting this pathway could lead to neuroprotective agents against ischemic stroke.
  18. pmc Neuroglobin protects the brain from experimental stroke in vivo
    Yunjuan Sun
    Buck Institute for Age Research, 8001 Redwood Boulevard, Novato, CA 94945, USA
    Proc Natl Acad Sci U S A 100:3497-500. 2003
    ..We conclude that Ngb acts as an endogenous neuroprotective factor in focal cerebral ischemia and may therefore represent a target for the development of new treatments for stroke...
  19. ncbi Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD
    J G Nutt
    Oregon Health and Science University, Portland 97201 3098, USA
    Neurology 60:69-73. 2003
    ..To assess the safety, tolerability, and biological activity of glial cell line-derived neurotrophic factor (GDNF) administered by an implanted intracerebroventricular (ICV) catheter and access port in advanced PD...
  20. ncbi A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia
    Tiziana Borsello
    Institut de Biologie Cellulaire et de Morphologie, Universite de Lausanne, Rue du Bugnon 9, CH 1005, Switzerland
    Nat Med 9:1180-6. 2003
    ..Protection correlated with prevention of an increase in c-Jun activation and c-Fos transcription. In view of its potency and long therapeutic window, this protease-resistant peptide is a promising neuroprotective agent for stroke...
  21. ncbi Hydrogen sulfide protects neurons from oxidative stress
    Yuka Kimura
    National Institute of Neuroscience, Kodaira, Tokyo, Japan
    FASEB J 18:1165-7. 2004
    ..Cystine (cysteine) is the rate-limiting substrate of glutathione synthesis. These observations reveal that H2S protects neurons from oxytosis by increasing the production of the antioxidant glutathione...
  22. ncbi Use of anti-aging herbal medicine, Lycium barbarum, against aging-associated diseases. What do we know so far?
    Raymond Chuen Chung Chang
    Laboratory of Neurodegenerative Diseases, Department of Anatomy, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China
    Cell Mol Neurobiol 28:643-52. 2008
    ..barbarum. We hope that new findings for L. barbarum will pave a new avenue for the use of Chinese medicine in modern evidence-based medicine...
  23. pmc Progesterone receptors: form and function in brain
    Roberta Diaz Brinton
    Department of Pharmacology and Pharmaceutical Sciences, University of Southern California, School of Pharmacy, 1985 Zonal Avenue, Los Angeles, CA 90089, USA
    Front Neuroendocrinol 29:313-39. 2008
    ....
  24. pmc Lycium barbarum polysaccharides reduce neuronal damage, blood-retinal barrier disruption and oxidative stress in retinal ischemia/reperfusion injury
    Suk Yee Li
    Eye Institute, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong
    PLoS ONE 6:e16380. 2011
    ..The present study suggests that LBP may have a neuroprotective role to play in ocular diseases for which I/R is a feature...
  25. pmc Stroke research at a crossroad: asking the brain for directions
    Costantino Iadecola
    Division of Neurobiology, Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, New York, USA
    Nat Neurosci 14:1363-8. 2011
    ..Learning how the brain triggers and implements these protective measures may advance our quest to treat stroke...
  26. ncbi Potential autophagy enhancers attenuate rotenone-induced toxicity in SH-SY5Y
    N Xiong
    Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei 430022, China
    Neuroscience 199:292-302. 2011
    ..Our results suggest that VPA and CBZ, the most commonly used anti-epilepsy and mood-stabilizing medications with low-risk and easy administration might be potential therapeutics for PD...
  27. pmc TREK-1, a K+ channel involved in neuroprotection and general anesthesia
    C Heurteaux
    Institut de Pharmacologie Moleculaire et Cellulaire, CNRS, Institut Paul Hamel, Sophia Antipolis, Valbonne, France
    EMBO J 23:2684-95. 2004
    ..Trek1-/- mice are also resistant to anesthesia by volatile anesthetics. TREK-1 emerges as a potential innovative target for developing new therapeutic agents for neurology and anesthesiology...
  28. ncbi Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia
    T M Tikka
    A. I. Virtanen Institute for Molecular Sciences, University of Kuopio, Kuopio, Finland
    J Immunol 166:7527-33. 2001
    ..Together, these results suggest that microglial activation contributes to NMDA excitotoxicity and that minocycline, a tetracycline derivative, represents a potential therapeutic agent for brain diseases...
  29. ncbi Neurovascular protection reduces early brain injury after subarachnoid hemorrhage
    S Park
    Department of Neurosurgery, Louisiana State University Health Sciences Center, Shreveport, LA 71130 3932, USA
    Stroke 35:2412-7. 2004
    ..We examined the relationships between apoptosis and the disruption of blood-brain barrier (BBB), brain edema, and mortality in an established endovascular perforation model in male Sprague-Dawley rats...
  30. ncbi Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity
    A Bal-Price
    Department of Biochemistry, University of Cambridge, Cambridge, CB2 1QW, United Kingdom
    J Neurosci 21:6480-91. 2001
    ..This may contribute to neuronal cell death in inflammatory, infectious, ischemic, and neurodegenerative diseases...
  31. pmc The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies
    Marwan Maalouf
    Department of Neurobiology, David Geffen School of Medicine, University of California, 63 323 CH5, Box 951763, Los Angeles, CA 90095 1763, USA
    Brain Res Rev 59:293-315. 2009
    ..The present review summarizes the neuroprotective effects of calorie restriction, of the ketogenic diet and of ketone bodies, and compares their putative mechanisms of action...
  32. pmc Resveratrol pretreatment protects rat brain from cerebral ischemic damage via a sirtuin 1-uncoupling protein 2 pathway
    D Della-Morte
    Cerebral Vascular Disease Research Center, Department of Neurology, Leonard M Miller School of Medicine, University of Miami, Miami, FL 33136, USA
    Neuroscience 159:993-1002. 2009
    ..In conclusion, in vivo resveratrol pretreatment confers neuroprotection similar to IPC via the SIRT1-UCP2 pathway...
  33. ncbi Antioxidants, oxidative stress, and degenerative neurological disorders
    R A Floyd
    Free Radical Biology and Aging Research Program, Oklahoma Medical Research Foundation and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City 73104, USA
    Proc Soc Exp Biol Med 222:236-45. 1999
    ..Outcomes of clinical trials on antioxidants will become less confusing as more knowledge is amassed on the basic processes involved...
  34. ncbi Neuroprotective effects of salidroside against beta-amyloid-induced oxidative stress in SH-SY5Y human neuroblastoma cells
    Li Zhang
    Jiangsu Institute of Nuclear Medicine, Key Laboratory of Nuclear Medicine, Ministry of Health, Wuxi, Jiangsu, China
    Neurochem Int 57:547-55. 2010
    ..These results suggest that salidroside has protective effects against Abeta(25-35)-induced oxidative stress, which might be a potential therapeutic agent for treating or preventing neurodegenerative diseases...
  35. ncbi Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury
    Emanuela Esposito
    Department of Clinical and Experimental Medicine and Pharmacology, School of Medicine, University of Messina, Italy
    Brain Behav Immun 25:1099-112. 2011
    ....
  36. ncbi Peroxisome proliferator-activated receptor-α agonists protect cortical neurons from inflammatory mediators and improve peroxisomal function
    Elizabeth Gray
    University of Bristol Institute of Clinical Neurosciences, Frenchay Hospital, Bristol BS16 1JB, UK
    Eur J Neurosci 33:1421-32. 2011
    ....
  37. ncbi Uncoupling protein-2 prevents neuronal death and diminishes brain dysfunction after stroke and brain trauma
    Gustav Mattiasson
    Wallenberg Neuroscience Center, BMC A13, 221 84 Lund, Sweden
    Nat Med 9:1062-8. 2003
    ..We propose that UCP-2 is an inducible protein that is neuroprotective by activating cellular redox signaling or by inducing mild mitochondrial uncoupling that prevents the release of apoptogenic proteins...
  38. pmc Discovery of a proneurogenic, neuroprotective chemical
    Andrew A Pieper
    Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 9152, USA
    Cell 142:39-51. 2010
    ..Prolonged administration of P7C3 to aged rats also enhanced neurogenesis in the dentate gyrus, impeded neuron death, and preserved cognitive capacity as a function of terminal aging. PAPERCLIP:..
  39. ncbi Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways
    R D Almeida
    Center for Neuroscience and Cell Biology and Department of Zoology, University of Coimbra, 3004 517 Coimbra, Portugal
    Cell Death Differ 12:1329-43. 2005
    ..The results indicate that the protective effect of BDNF in hippocampal neurons against glutamate toxicity is mediated by the PI3-K and the Ras/MAPK signaling pathways, and involves a long-term change in protein synthesis...
  40. pmc Diagnosis and treatment of Parkinson disease: molecules to medicine
    Joseph M Savitt
    Institute for Cell Engineering, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    J Clin Invest 116:1744-54. 2006
    ....
  41. pmc Cyclooxygenase-2-specific inhibitor improves functional outcomes, provides neuroprotection, and reduces inflammation in a rat model of traumatic brain injury
    Jonas J Gopez
    Department of Neurosurgery, Temple University School of Medicine, Philadelphia, Pennsylvania, USA
    Neurosurgery 56:590-604. 2005
    ..A growing literature supports the benefit of COX2-specific inhibitors in treating brain injuries...
  42. ncbi Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy
    Nadia Stefanova
    Clinical Neurobiology Unit, Neurodegeneration Research Laboratory, Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
    Mov Disord 22:2196-203. 2007
    ....
  43. ncbi Resveratrol and neurodegenerative diseases: activation of SIRT1 as the potential pathway towards neuroprotection
    Merce Pallas
    Facultat de Farmacia, Institut de Biomedicina IBUB, Centro de Investigación de Biomedicina en Red de Enfermedades Neurodegenerativas, Universitat de Barcelona, Nucli Universitari de Pedralbes, Barcelona, Spain
    Curr Neurovasc Res 6:70-81. 2009
    ..In addition, we discuss the possibility of using resveratrol in the treatment of neurodegenerative diseases...
  44. ncbi Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats
    Yi Zhao
    Institute of Pharmacology, University Hospital of Schleswig Holstein, Campus Kiel Hospitalstrasse 4 24105 Kiel, Germany
    FASEB J 20:1162-75. 2006
    ..Our data provide evidence that activation of neuronal PPARgamma considerably contributes to neuroprotection by prevention of COX-2 up-regulation in vitro and in peri-infarct brain areas...
  45. ncbi Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases
    Orly Weinreb
    Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, Rappaport Family Research Institute, Technion Faculty of Medicine, 31096 Haifa, Israel
    J Nutr Biochem 15:506-16. 2004
    ..in well controlled epidemiological studies, aimed to alter brain aging processes and to serve as possible neuroprotective agents in progressive neurodegenerative disorders such as Parkinson's and Alzheimer's diseases...
  46. ncbi Nuclear Ca2+ and the cAMP response element-binding protein family mediate a late phase of activity-dependent neuroprotection
    Sofia Papadia
    Centre for Neuroscience Research, University of Edinburgh, Summerhall, Edinburgh EH9 1QH, United Kingdom
    J Neurosci 25:4279-87. 2005
    ..Thus, activity-dependent neuroprotection comprises two mechanistically distinct phases that differ in their spatial requirements for calcium and in their reliance on the CREB family...
  47. ncbi Oxidative damage in the central nervous system: protection by melatonin
    R J Reiter
    Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio 78284 7762, USA
    Prog Neurobiol 56:359-84. 1998
    ..Since endogenous melatonin levels fal 1 markedly in advanced age, the implication of these findings is that the loss of this antioxidant may contribute to the incidence or severity of some age-associated neurodegenerative diseases...
  48. pmc Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial
    Guomin Xiao
    Department of Neurosurgery and Neurotrauma Center, Affiliated Hospital, College of Medicine, Hangzhou Normal University, Hangzhou 310015, China
    Crit Care 12:R61. 2008
    ..The aim of the present clinical study was to assess the longer-term efficacy of progesterone on the improvement in neurologic outcome of patients with acute severe TBI...
  49. ncbi Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease
    Jin Xu
    Department of Neurology, Harvard Medical School and Division of Neuroscience, The Children s Hospital, Boston, Massachusetts, USA
    Nat Med 8:600-6. 2002
    ..Thus, accumulation of soluble alpha-synuclein protein complexes can render endogenous dopamine toxic, suggesting a potential mechanism for the selectivity of neuronal loss in PD...
  50. ncbi Leptin-mediated cell survival signaling in hippocampal neurons mediated by JAK STAT3 and mitochondrial stabilization
    Zhihong Guo
    Laboratory of Neurosciences and National Institute on Aging Intramural Research Program, Baltimore, MD 21224, USA
    J Biol Chem 283:1754-63. 2008
    ..By enhancing mitochondrial resistance to apoptosis and excitotoxicity, our findings suggest that leptin signaling serves a neurotrophic function in the developing and adult hippocampus...
  51. ncbi Transforming growth factor-beta 1 increases bad phosphorylation and protects neurons against damage
    Yuan Zhu
    Institut für Pharmakologie und Toxikologie and Pharmazeutische Chemie, Philipps Universitat, D 35032 Marburg, Germany
    J Neurosci 22:3898-909. 2002
    ..Together, we demonstrate that TGF-beta1 suppresses Bad expression under lesion conditions, increases Bad phosphorylation, and activates the MAPK/Erk pathway, which may contribute to its neuroprotective activity...
  52. pmc Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury
    M L Brines
    The Kenneth S Warren Laboratories, 765 Old Saw Mill River Road, Tarrytown, NY 10591, USA
    Proc Natl Acad Sci U S A 97:10526-31. 2000
    ..Given r-Hu-EPO's excellent safety profile, clinical trials evaluating systemically administered r-Hu-EPO as a general neuroprotective treatment are warranted...
  53. pmc Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease
    Y Du
    Departmens of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Proc Natl Acad Sci U S A 98:14669-74. 2001
    ..Thus, NO appears to play an important role in MPTP neurotoxicity. Neuroprotective tetracyclines may be effective in preventing or slowing the progression of Parkinson's and other neurodegenerative diseases...
  54. pmc Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis
    Rachel Tesla
    Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Proc Natl Acad Sci U S A 109:17016-21. 2012
    ..We propose that the chemical scaffold represented by P7C3 and P7C3A20 may provide a basis for the discovery and optimization of pharmacologic agents for the treatment of ALS...
  55. ncbi Involvement of ROS in BBB dysfunction
    Pamela B L Pun
    Defence Medical and Environmental Research Institute, DSO National Laboratories, Singapore
    Free Radic Res 43:348-64. 2009
    ..This review explores some of the pathways both upstream and downstream of ROS that have been implicated in increased BBB permeability and discusses the role of ROS and antioxidants in neuropathology...
  56. ncbi Neuroprotection in glaucoma: recent and future directions
    Helen V Danesh-Meyer
    Department of Ophthalmology, University of Auckland, Auckland, New Zealand
    Curr Opin Ophthalmol 22:78-86. 2011
    ..This review focuses on strategies for neuroprotection and summarizes preclinical studies that have investigated potential agents over the last 2 years...
  57. ncbi Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction
    Ming Ren
    Molecular Neurobiology Section, National Institute of Mental Health, National Institutes of Health, 10 Center Drive, MSC 1363, Bethesda, MD 20892 1363, USA
    J Neurochem 89:1358-67. 2004
    ..Altogether, our results demonstrate that VPA is neuroprotective in the cerebral ischemia model and suggest that the protection mechanisms may involve HDAC inhibition and HSP induction...
  58. ncbi Lutein enhances survival and reduces neuronal damage in a mouse model of ischemic stroke
    Suk Yee Li
    Eye Institute, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong
    Neurobiol Dis 45:624-32. 2012
    ..The aim of this study is to investigate the protective roles of lutein in cerebral I/R injury...
  59. ncbi A neural cell adhesion molecule-derived peptide reduces neuropathological signs and cognitive impairment induced by Abeta25-35
    B Klementiev
    ENKAM Pharmaceuticals A S, Copenhagen, Denmark
    Neuroscience 145:209-24. 2007
    ....
  60. ncbi Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades
    M Digicaylioglu
    Center for Neuroscience and Aging Research, The Burnham Institute, La Jolla, CA 92037, USA
    Nature 412:641-7. 2001
    ..Thus neuronal EPORs activate a neuroprotective pathway that is distinct from previously well characterized Jak and NF-kappaB functions. Moreover, this EPO effect may underlie neuroprotection mediated by hypoxic-ischaemic preconditioning...
  61. ncbi Neuronal injury in rat model of permanent focal cerebral ischemia is associated with activation of autophagic and lysosomal pathways
    Ya Dan Wen
    Department of Pharmacology and Laboratory of Aging and Nervous Diseases, Soochow University School of Medicine, Suzhou, China
    Autophagy 4:762-9. 2008
    ..These results demonstrate that ischemic insult activates autophagy and an autophagic mechanism may contribute to ischemic neuronal injury. Thus, autophagy may be a potential target for developing a novel therapy for stroke...
  62. ncbi Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice
    Jennifer E A Wells
    University of Calgary, 3330 Hospital Drive, Calgary, Alberta, Canada T2N 4N1
    Brain 126:1628-37. 2003
    ..Finally, a comparison of minocycline against the currently approved treatment for acute SCI in humans, methylprednisolone, demonstrated superior behavioural recovery in the minocycline-treated animals...
  63. pmc Neuroprotective effects of curcumin
    Greg M Cole
    Greater Los Angeles Veterans Affairs Healthcare System, Geriatric Research, Education, and Clinic Center, Sepulveda, CA 91343, USA
    Adv Exp Med Biol 595:197-212. 2007
    ..Promising results have already led to ongoing pilot clinical trials...
  64. ncbi Increases in β-amyloid protein in the hippocampus caused by diabetic metabolic disorder are blocked by minocycline through inhibition of NF-κB pathway activation
    Zhiyou Cai
    Department of Neurology, Affiliated Hospital, Guangdong Medical College, Zhanjiang, China
    Pharmacol Rep 63:381-91. 2011
    ..In sum, diabetes contributes to the activation of the NF-κB pathway and upregulates BACE1 and Aβ. Minocycline downregulates Aβ in the hippocampus by inhibiting NF-κB pathway activation...
  65. ncbi Circulating insulin-like growth factor I mediates the protective effects of physical exercise against brain insults of different etiology and anatomy
    E Carro
    Laboratory of Neuroendocrinology, Cajal Institute, Consejo Superior de Investigaciones Cientificas, 28002 Madrid, Spain
    J Neurosci 21:5678-84. 2001
    ..These findings also support the use of IGF-I as a therapeutical aid in brain diseases coursing with either acute or progressive neuronal death...
  66. ncbi Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents
    Ravinder K Kaundal
    Department of Pharmacology and Toxicology of the National Institute of Pharmaceutical Education and Research NIPER, Mohali, Punjab, India
    Drug News Perspect 23:241-56. 2010
    ..This article discusses evidence and mechanisms supporting the neuroprotective effects of PPARgamma agonists in central nervous system disorders...
  67. ncbi CORM-3, a carbon monoxide-releasing molecule, alters the inflammatory response and reduces brain damage in a rat model of hemorrhagic stroke
    Andriy Yabluchanskiy
    Department of Surgical Research, Northwick Park Institute for Medical Research, Harrow, Middlesex, UK
    Crit Care Med 40:544-52. 2012
    ..We assessed the effect of CORM-3, a water-soluble carbon monoxide-releasing molecule possessing anti-inflammatory properties, on inflammation and brain injury after intracerebral hemorrhage...
  68. pmc Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease
    Xin Wang
    Neuroapoptosis Laboratory, Department of Neurosurgery, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 100:10483-7. 2003
    ..Our results further delineate the mechanism by which minocycline mediates its remarkably broad neuroprotective effects...
  69. ncbi STAT3 activation in photoreceptors by leukemia inhibitory factor is associated with protection from light damage
    Yumi Ueki
    Oklahoma Center for Neuroscience, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
    J Neurochem 105:784-96. 2008
    ..Our data suggest that photoreceptor protection in response to LIF can be directly mediated by activation of STAT3 in photoreceptors...
  70. ncbi Emodin-induced microglial apoptosis is associated with TRB3 induction
    Xueping Zhou
    the Clinical Research Institute, First College of Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, China
    Immunopharmacol Immunotoxicol 33:594-602. 2011
    ..Our findings provide a novel molecular basis through which emodin exerts neuroprotective effects, treating brain injury after intracerebral hemorrhage...
  71. ncbi The role of ASIC1a in neuroprotection elicited by quercetin in focal cerebral ischemia
    Anand Kumar Pandey
    Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, Brig SK Mazumdar Road, Delhi 110054, India
    Brain Res 1383:289-99. 2011
    ..These studies suggest the neuroprotective role of quercetin in focal cerebral ischemia by regulation of ASIC1a...
  72. ncbi Insights into the putative catechin and epicatechin transport across blood-brain barrier
    Ana Faria
    Department of Biochemistry U38 FCT, Faculty of Medicine, University of Porto, Al Prof Hernani Monteiro, 4200 319 Porto, Portugal
    Food Funct 2:39-44. 2011
    ..Nevertheless, the information obtained by this study is valuable for the new insights about flavan-3-ols transport...
  73. ncbi Curcumin improves outcomes and attenuates focal cerebral ischemic injury via antiapoptotic mechanisms in rats
    Jing Zhao
    Department of Pathophysiology, Molecular Medicine and Tumor Center, Chongqing Medical University, Chongqing, China
    Neurochem Res 35:374-9. 2010
    ..Inhibition of oxidative stress with curcumin treatment improves outcomes after focal cerebral ischemia. This neuroprotective effect is likely exerted by antiapoptotic mechanisms...
  74. ncbi ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury
    David W Wright
    Department of Emergency Medicine, School of Medicine of Emory University, Atlanta, GA, USA
    Ann Emerg Med 49:391-402, 402.e1-2. 2007
    ..Laboratory evidence indicates that progesterone has potent neuroprotective effects. We conducted a pilot clinical trial to assess the safety and potential benefit of administering progesterone to patients with acute traumatic brain injury...
  75. pmc The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease
    E Ilijic
    Department of Physiology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Neurobiol Dis 43:364-71. 2011
    ..Nothing is known to slow the progression of the disease, making the identification of potential neuroprotective agents of great clinical importance...
  76. ncbi Delta opioid peptide (D-Ala 2, D-Leu 5) enkephalin: linking hibernation and neuroprotection
    Cesario V Borlongan
    Department of Neurology and Institute of Molecular Medicine and Genetics, Medical College of Georgia, 1120 15th Street, Augusta GA 30912 3200, USA
    Front Biosci 9:3392-8. 2004
    ..These results taken together suggest that DADLE stands as a novel therapeutic agent. In this review paper, we present laboratory evidence supporting the use of DADLE for protection of peripheral and central nervous system...
  77. ncbi Pretreatment with electroacupuncture induces rapid tolerance to focal cerebral ischemia through regulation of endocannabinoid system
    Qiang Wang
    Department of Anesthesiology, Xijing Hospital, Fourth Military Medical University, Xi an 710032, Shaanxi Province, China
    Stroke 40:2157-64. 2009
    ..The present study was aimed to investigate the involvement of the endocannabinoid system in the early neuroprotection conferred by EA pretreatment in the animal model of focal cerebral ischemia...
  78. ncbi Preconditioning with isoflurane produces dose-dependent neuroprotection via activation of adenosine triphosphate-regulated potassium channels after focal cerebral ischemia in rats
    Lize Xiong
    Department of Anesthesiology, Xijing Hospital, Fourth Military Medical University, Xi an, Shaanxi, China
    Anesth Analg 96:233-7, table of contents. 2003
    ..The study demonstrated that repeated Iso anesthesia induces ischemic tolerance in rats in a dose-response manner. GLB, an adenosine triphosphate-regulated potassium channel blocker, abolished the tolerance induced by Iso...
  79. ncbi Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration
    Toshiyuki Araki
    Department of Pathology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Science 305:1010-3. 2004
    ..These findings suggest that novel therapeutic strategies directed at increasing the supply of NAD and/or Sir2 activation may be effective for treatment of diseases characterized by axonopathy and neurodegeneration...
  80. ncbi Molecular and cellular mechanisms of neuroprotection by vascular endothelial growth factor
    Feng Yan Sun
    National Key Laboratory of Medical Neurobiology, Shanghai Medical College of Fudan University, 138 Xue Yuan Road, Shanghai 200 032, P R China
    J Neurosci Res 79:180-4. 2005
    ....
  81. ncbi Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice
    Kavon Rezai-Zadeh
    Rashid Laboratory for Developmental Neurobiology, Silver Child Development Center, Department of Psychiatry and Behavioral Medicine, and Department of Neurosurgery, University of South Florida, Tampa, FL 33613, USA
    Brain Res 1214:177-87. 2008
    ..Taken together, these data further the notion of EGCG dietary supplementation as a potentially safe and effective prophylaxis for Alzheimer's disease...
  82. ncbi Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons
    Hui Ming Gao
    Neuropharmacology Section, Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences National Institutes of Health, Research Triangle Park, North Carolina 27709, USA
    J Neurosci 23:6181-7. 2003
    ..This study also suggested that microglial NADPH oxidase may be a promising target for PD treatment...
  83. ncbi Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action
    Hyeon Ju Kim
    Molecular Neurobiology Section, National Institute of Mental Health, National Institutes of Health, Building 10, Bethesda, MD 20892 1363, USA
    J Pharmacol Exp Ther 321:892-901. 2007
    ..Given that there is no effective treatment for stroke, HDAC inhibitors, such as VPA, SB, and TSA, should be evaluated for their potential use for clinical trials in stroke patients...
  84. ncbi After cellular internalization, quercetin causes Nrf2 nuclear translocation, increases glutathione levels, and prevents neuronal death against an oxidative insult
    Florencia Arredondo
    Departamento de Neuroquimica, Instituto de Investigaciones Biologicas Clemente Estable, 11600 Montevideo, Uruguay
    Free Radic Biol Med 49:738-47. 2010
    ..Our findings suggest alternative mechanisms of quercetin neuroprotection beyond its long-established ROS scavenging properties, involving Nrf2-dependent modulation of the GSH redox system...
  85. ncbi Potassium channel blockers attenuate hypoxia- and ischemia-induced neuronal death in vitro and in vivo
    Ling Wei
    Center for the Study of Nervous System Injury and Department of Neurology, Washington University School of Medicine, St Louis, MO 63110, USA
    Stroke 34:1281-6. 2003
    ....
  86. ncbi The protective effects of Achyranthes bidentata polypeptides against NMDA-induced cell apoptosis in cultured hippocampal neurons through differential modulation of NR2A- and NR2B-containing NMDA receptors
    Hongmei Shen
    Medical School of Soochow University, Suzhou 215123, PR China
    Brain Res Bull 77:274-81. 2008
    ..Our data might suggest that ABPP may also prove to be a potential neuroprotective therapy owing to its differential modulation of NR2A- and NR2B-containing NMDA receptors...
  87. ncbi Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke
    Louise D McCullough
    Department of Neurology, University of Connecticut Health Center, Farmington, Connecticut 06030, USA
    J Biol Chem 280:20493-502. 2005
    ..The ability to manipulate pharmacologically neuronal energy balance during ischemia represents an innovative approach to neuroprotection...
  88. ncbi Neuroprotective effects of leptin against ischemic injury induced by oxygen-glucose deprivation and transient cerebral ischemia
    Feng Zhang
    Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Stroke 38:2329-36. 2007
    ..Leptin receptors are also present in other cell types, and a potent antiapoptotic effect for leptin has recently been reported. We investigated whether leptin was neuroprotective against ischemic brain injury...
  89. pmc Neuronal PPARgamma deficiency increases susceptibility to brain damage after cerebral ischemia
    Xiurong Zhao
    Stroke Program, Department of Neurology, University of Texas, Houston, Medical School, Houston, Texas 77030, USA
    J Neurosci 29:6186-95. 2009
    ..Therefore, we conclude that PPARgamma in neurons play an essential protective function and that PPARgamma agonists may have utility in neuronal self-defense, in addition to their well established anti-inflammatory effect...
  90. ncbi ERK- and Akt-dependent neuroprotection by erythropoietin (EPO) against glyoxal-AGEs via modulation of Bcl-xL, Bax, and BAD
    Jianfeng Shen
    Laboratory of Clinical Visual Sciences, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Shanghai Jiao Tong University School of Medicine, Shanghai, China
    Invest Ophthalmol Vis Sci 51:35-46. 2010
    ..To characterize the neuroprotective mechanisms of erythropoietin (EPO) against the stress of glyoxal-advanced glycation end products (AGEs) in retinal neuronal cells...
  91. ncbi Polysaccharides from wolfberry antagonizes glutamate excitotoxicity in rat cortical neurons
    Yuen Shan Ho
    Laboratory of Neurodegenerative Diseases, Department of Anatomy, LKS Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong SAR, China
    Cell Mol Neurobiol 29:1233-44. 2009
    ..Taken together, LBA exerted significant neuroprotective effects on cultured cortical neurons exposed to glutamate...
  92. ncbi Neuroprotective effects of salidroside in the PC12 cell model exposed to hypoglycemia and serum limitation
    Shu Yu
    Jiangsu Key Laboratory of Neuroregeneration, Nantong University, Nantong, JS 226001, People s Republic of China
    Cell Mol Neurobiol 28:1067-78. 2008
    ..Our findings might raise a possibility of potential therapeutic applications of salidroside for preventing and treating cerebral ischemic and neurodegenerative diseases...
  93. ncbi Characterization of the effects of anti-aging medicine Fructus lycii on beta-amyloid peptide neurotoxicity
    Man Shan Yu
    Laboratory of Neurodegenerative Diseases, Department of Anatomy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, P R China
    Int J Mol Med 20:261-8. 2007
    ..As herbal medicine has received increasing attention for the treatment of AD, our study will open a window for the development of a neuroprotective agent for anti-aging from Chinese medicine...
  94. ncbi Tripchlorolide protects neuronal cells from microglia-mediated beta-amyloid neurotoxicity through inhibiting NF-kappaB and JNK signaling
    Xiao Dong Pan
    Department of Neurology, Union Hospital of Fujian Medical University, Fuzhou, Fujian, People s Republic of China
    Glia 57:1227-38. 2009
    ..Therefore, T4 may be an effective agent in modulating neuroinflammatory process in AD...
  95. ncbi Minocycline delays disease onset and mortality in a transgenic model of ALS
    Ludo Van Den Bosch
    Laboratory for Neurobiology, Campus Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Neuroreport 13:1067-70. 2002
    ..These results demonstrate that interference with immuno-inflammatory responses has a beneficial effect in the ALS mice model, suggesting this to be a potential new strategy to treat ALS...
  96. ncbi The neuroprotective effect of xenon administration during transient middle cerebral artery occlusion in mice
    H Mayumi Homi
    Department of Anesthesiology Multidisciplinary Neuroprotection Laboratories, Duke University Medical Center, Durham, North Carolina, USA
    Anesthesiology 99:876-81. 2003
    ..However, its putative neuroprotective properties have not been evaluated in focal cerebral ischemia. The purpose of this study was to determine if xenon offers neuroprotection in a mouse model of middle cerebral artery occlusion...
  97. ncbi Neuroprotective effects of Lycium barbarum Lynn on protecting retinal ganglion cells in an ocular hypertension model of glaucoma
    Hiu Chi Chan
    Department of Anatomy, Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR
    Exp Neurol 203:269-73. 2007
    ..barbarum against neurodegeneration in the retina of rat OH model. The results demonstrate that this extract may be a potential candidate for the development of neuroprotective drug against the loss of RGCs in glaucoma...
  98. ncbi Edaravone prevents kainic acid-induced neuronal death
    Ryohei Miyamoto
    Department of Pediatrics, Osaka Medical College, Japan
    Brain Res 1209:85-91. 2008
    ..Patients who develop status epilepticus are unlikely to receive adequate antioxidant therapy before the onset, so it is an advantage that Ed can prevent neuronal death even when administered after seizures...
  99. ncbi Rapamycin is a neuroprotective treatment for traumatic brain injury
    S Erlich
    Department of Neurobiochemistry, Tel Aviv University, Ramat Aviv 69978, Israel
    Neurobiol Dis 26:86-93. 2007
    ....
  100. ncbi Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94
    M Asahi
    Department of Neurology, Massachusetts General Hospital, and Harvard Medical School, Charlestown 02129, USA
    J Cereb Blood Flow Metab 20:1681-9. 2000
    ..These data demonstrate that MMP-9 plays a deleterious role in the development of brain injury after focal ischemia...
  101. ncbi Nutraceutical antioxidants as novel neuroprotective agents
    Natalie A Kelsey
    Department of Biological Sciences and Eleanor Roosevelt Institute, University of Denver, Denver, Colorado 80208, USA
    Molecules 15:7792-814. 2010
    ..Here, we review the literature pertaining to these various classes of nutraceutical antioxidants and discuss their potential therapeutic value in neurodegenerative diseases...

Research Grants71

  1. Multi-targeted Countermeasures against Acute and Delayed Effects of OP Exposure
    John A Butera; Fiscal Year: 2013
    ..It has been established that inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1) are useful neuroprotective agents especially when the neurodegeneration is caused by excitotoxic insult...
  2. Protection of Brain Injury from Cyanide Poisoning by Carnosic Acid
    Stuart A Lipton; Fiscal Year: 2013
    ..To investigate neuroprotective effects of CA in an in vitro model of cyanide poisoning. Specific Aim 2. To examine neuroprotective effects of CA in an in vivo mouse model mimicking the effects of cyanide ingestion. ..
  3. STRESS, ADRENAL STEROIDS AND THE BRAIN
    Bruce S McEwen; Fiscal Year: 2013
    ..functions involve interactions among endocannabinoids, excitatory amino acids and glucocorticoids and neuroprotective agents, such as the chaperone, BAG1...
  4. Role of endothelin receptors in glaucomatous optic neuropathy
    Raghu R Krishnamoorthy; Fiscal Year: 2013
    ..The information gained from this study could be useful in developing endothelin receptor antagonists as neuroprotective agents in glaucoma treatment.
  5. Novel Mitochondrial Targeted Neuroprotectants for Glaucoma
    Leonard Levin; Fiscal Year: 2009
    ....
  6. Stem cell-mediated delivery of neurotrophic factors for treatment of glaucoma
    Donald S Sakaguchi; Fiscal Year: 2010
    ..is that transplanted, genetically modified bone marrow-derived stem cells can be used as effective neuroprotective agents to mediate preservation and rescue of visual function in the rat model of experimental glaucoma...
  7. Novel Therapeutics for Neurotropic Alphaviruses
    David J Miller; Fiscal Year: 2013
    ..analyze the in vivo pharmacokinetics and efficacy of candidate antivirals, including combination treatment with neuroprotective agents;and (4) isolate and characterize novel compounds with antiviral activity derived from marine microbes.
  8. Screen for Small Molecule Regulators of Retinal Progenitor Epithelial Cell Phagoc
    CHARLES YOON HYUNG CHO; Fiscal Year: 2010
    ..This proposal seeks to develop new assay technology that could test several hundred thousand compounds to speed the development of new treatments for this devastating disease. ..
  9. Neuroprotection by Mitochondria-targeted Antioxidants
    ANUMANTHA GOUNDER KANTHASAMY; Fiscal Year: 2013
    ....
  10. Rapid ischemic tolerance: Synaptic re-organization and reduced excitotoxicity
    Robert Meller; Fiscal Year: 2012
    ..endogenous protective mechanisms that can be translated into effective rapid-acting, but long lasting, neuroprotective agents for stroke or where ischemia may be predicted for example, heart bypass surgery...
  11. Protein Acetylation in Glaucomatous Optic Neuropathy
    Craig E Crosson; Fiscal Year: 2013
    ..neuroinflammatory processes in the optic nerve and retina;and 3) provide a rational basis for the development of HDAC inhibitors as neuroprotective agents for the treatment of glaucoma and other optic neuropathies.
  12. Neuroprotection Against Parkinsonian Cell Death
    Jun Chen; Fiscal Year: 2013
    ..Thus, the long-term goal of this proposal is to identify novel neuroprotective agents that are capable of blocking the apoptosis-signaling pathways in dopaminergic neurons and the neurotoxic ..
  13. Development of Potent/Selective Lipoxygenase Therapeutics Against Stroke Injury
    Theodore R Holman; Fiscal Year: 2013
    ..Recent failures in testing of neuroprotective agents have highlighted the need for new approaches to acute stroke treatment...
  14. Age influences neuropoietic signaling at the neurovascular unit following stroke
    Jason D Huber; Fiscal Year: 2012
    ..Our results will lead to a better understanding of the role age, plays in stroke etiology, progression, and recovery. ..
  15. Broadly Neuroprotective Drug for TBI
    Fernando Gomez Pinilla; Fiscal Year: 2010
    ..We expect to generate valuable pre-clinical information that will entitle us to initiate the steps for seeking IND approval. ..
  16. Neuroprotective agents for retinal diseases
    CHRIS LINDSEY; Fiscal Year: 2012
    ..At this time, there are no effective therapies that can restore mitochondrial function to promote photoreceptor repair/regeneration. Thus, research is needed to develop new drugs that promote mitochondrial function in the retina. ..
  17. siRNA Therapy and Imaging Assessment in Ischemic Stroke
    Marytheresa Ifediba; Fiscal Year: 2012
    ..As a proof-of-principle that MPAP-siRNA probes are effective neuroprotective agents, we propose to fully characterize and test probes directed against c-src (src) that is implicated in ..
  18. Protection of Mice From Lethal Alphavirus Encephalitis
    David N Irani; Fiscal Year: 2010
    ....
  19. STUDIES IN GLAUCOMATOUS OPTIC NERVE DAMAGE
    John C Morrison; Fiscal Year: 2013
    ..Successful development of the CEI model in rodents will simplify and accelerate the study of glaucomatous optic nerve damage and testing of potential neuroprotective agents.
  20. Mapping Lipid Oxidation in Traumatic Brain Injury by Mass Spectrometric Imaging
    Valerian E Kagan; Fiscal Year: 2013
    ..Overall, IMS technology and the underlying contribution of dyshomeostasis of mitochondrial CL and extramitochondrial PS are likely to be important for TBI studies and have implications for other CNS disorders. ..
  21. In Vivo Efficacy of New Neuroprotective Drugs
    DAVID R SCHUBERT; Fiscal Year: 2010
    ..These are experiments that are required for us to move these drugs toward the clinic. ..
  22. Thrombin Mediated Cytotoxicity during Cerebral Ischemia
    Patrick D Lyden; Fiscal Year: 2013
    ....
  23. Spinocerebellar Ataxia Type 2 Gene and Gene Product
    Stefan M Pulst; Fiscal Year: 2013
    ..Neither symptomatic nor neuroprotective agents have been identified for the treatment of human ataxias...
  24. Characterizing Beta Lactams as Neuroprotectants for Amyotrophic Lateral Sclerosis
    Jeffrey D Rothstein; Fiscal Year: 2010
    ..These sequential phases will set the stage for future practical translation towards rational clinical trial design. ..
  25. The role of PI3K/Akt pathway in the pathogenesis and treatment of Krabbe disease
    TUBA FEHR; Fiscal Year: 2012
    ..Aim 3 will test the hypothesis that GSK3[unreadable] inhibitors can be used as neuroprotective agents that will synergize with BMT to improve disease symptoms in twitcher mouse...
  26. Drugs of abuse and the epigenetic and signaling pathways controlling HIV latency
    Richard M Ransohoff; Fiscal Year: 2013
    ..latency and neurodegeneration, and extensive evaluations of the potential of nuclear receptor agonists as neuroprotective agents. We believe that the systematic studies we have proposed here will set the stage for improved clinical ..
  27. Novel up-regulators of NF-kB activity: effect on MnSOD and TBI in vitro models
    Maurizio Grimaldi; Fiscal Year: 2012
    ..Evidence collected from these studies could spin off a larger drug discovery program. ..
  28. Pursuing purine pathways to clinical trials for Parkinson's disease
    Michael A Schwarzschild; Fiscal Year: 2012
    ..program to a fully integrated translational endeavor dedicated to developing clinical trials of putative neuroprotective agents. Urate is a particularly promising candidate because of its unprecedented ability to predict both the risk ..
  29. IMAGING BIOMARKERS FOR RADIATION-INDUCED NECROSIS
    Joel Richard Garbow; Fiscal Year: 2013
    ....
  30. New York-Presbyterian NETT Consortium
    Stephan A Mayer; Fiscal Year: 2011
    ..ischemic stroke, midazolam infusion for refractory status epilepticus, and clinical trials evaluating neuroprotective agents for acute stroke, thrombolytic therapy for intraventricular hemorrhage, and ultra-early hemostatic therapy ..
  31. Neuroprotective and Antiviral Effects of BMD-101 and BMD-104 in HIV Infection
    Christopher G Conrad; Fiscal Year: 2011
    ..Based on these premises, we developed a novel neurotoxicity assay for neuroprotective agents which utilizes rat and human primary neuronal cultures...
  32. Phase II Trial of Tiopronin in Aneurysmal Subarachnoid Hemorrhage
    EDWARD SANDER CONNOLLY; Fiscal Year: 2011
    ..This would spark further study that could further explore neuroprotective pre-treatment of cerebral ischemia, and thus help neutralize a major source of morbidity and mortality in this disease process. ..
  33. Oxidative Stress and Pathological Glutamate Release in Stroke
    Alexander A Mongin; Fiscal Year: 2013
    ..abstract_text> ..
  34. Chromosomal and Hormonal Contributions to Sex Differences in Ischemic Stroke.
    LOUISE DEBORAH MCCULLOUGH; Fiscal Year: 2013
    ..Identification of sex selective cell death mechanisms has significant translational relevance, as neuroprotective agents that are efficacious in one sex may exacerbate injury in the other...
  35. Canonical Transient Receptor Potential Channels and Excitotoxicity
    Fang Zheng; Fiscal Year: 2010
    ..However, efforts to develop ionotropic glutamate receptor antagonists as neuroprotective agents have yet to be successful;alternative molecular targets for developing neuroprotective compounds need to ..
  36. Novel Neuroprotective Treatment for Parkinson's Disease
    Aloke K Dutta; Fiscal Year: 2013
    ..besides providing symptomatic relief in PD with less motor complications, have also been shown to act as neuroprotective agents. A D3 preferring compound D-264 derived from our novel hybrid template was shown to be neuroprotective in ..
  37. UCLA SPOTRIAS CENTER APPLICATION RENEWAL-PROGRAM PROJECT
    Jeffrey L Saver; Fiscal Year: 2012
    ..This trial will be the first formal study of endovascular infusion of neuroprotective agents, a highly promising complementary strategy to endovascular recanalization...
  38. Estrogen-neuroprotection due to astroglial Glu transporters occurs via TGF-a/b1
    EUN SOOK YU LEE; Fiscal Year: 2013
    ..abstract_text> ..
  39. Neuronal autophagy inducers as an approach to treat diseases of the central nervo
    Robert Greenhouse; Fiscal Year: 2013
    ..These studies will provide the foundation for future Phase 2 studies to identify a clinical candidate to alow ultimately for human testing as a treatment for HD and possibly other neurodegenerative diseases. ..
  40. Stroke Treatment by Chemically-Induced Hypothermia
    Shan Ping Yu; Fiscal Year: 2012
    ..Our ultimate goal is to advance the drug-induced hypothermia therapy to the clinic. ..
  41. Pathways of HIV neurodegeneration and dimethyl fumarate (DMF/MMF) neuroprotection
    DENNIS LARRY KOLSON; Fiscal Year: 2013
    ..This should provide a rationale for a future clinical trial in HIV patients. ..
  42. EP2 Allosteric Potentiators for Subarachnoid Hemorrhage
    Raymond J Dingledine; Fiscal Year: 2012
    ..b>Neuroprotective agents can be administered to this population prior to the ischemic event under intensive care monitoring...
  43. Novel Clinical and Ocular Imaging Outcomes with Long-Term Follow-Up in MS
    Laura Balcer; Fiscal Year: 2010
    ..in MS clinical trials, particularly for the anticipated next generation of trials that will involve neuroprotective agents. While our cross-sectional, preliminary longitudinal, and clinical trial data represent a significant step ..
  44. Early Biomarkers in Neonatal Brain Injury
    Sonia L Bonifacio; Fiscal Year: 2013
    ..and advanced imaging techniques to evaluate brain metabolism and identify neonates that may benefit from neuroprotective agents and strategies...
  45. Neuroprotective drugs for A-T
    DAVID WASSARMAN; Fiscal Year: 2013
    ....
  46. Insecticide Action at the Local Anesthetic Receptor
    David M Soderlund; Fiscal Year: 2011
    ..This research will provide new insight into the structure of the local anesthetic receptor and its role in the neurotoxic actions of PTIs. ..
  47. Pilot Proteomics Center for HIV-Related Dementia and Drug Abuse
    Robert J Cotter; Fiscal Year: 2010
    ..This has posed unique challenges for conducing clinical trials with neuroprotective agents and for managing this patient population...
  48. Ceramide and Oligodendrocyte Protection in Stroke
    Tatyana I Gudz; Fiscal Year: 2013
    ..It will improve the treatment and the quality of life of Veterans that will ultimately ameliorate the impact of the burden of care on the families and the American public. ..
  49. Defining Neurotherapeutic Targets in Hypoxia-Induced CHOP-10 Signaling Networks
    Marc W Halterman; Fiscal Year: 2012
    ..We anticipate that our results will aid in the identification of novel and tractable therapeutics for stroke. ..
  50. Neuroprotective Actions of Thiazolidinediones
    Sophia Sundararajan; Fiscal Year: 2009
    ..Clinical trials of neuroprotective agents have failed to show efficacy and it is believed that this failure is due to the inability to administer ..
  51. Peroxisomal Biogenesis after Cerebral Ischemia
    Nabil J Alkayed; Fiscal Year: 2013
    ..effects of ischemia on neurons once stroke takes place are still lacking, and clinical trials using neuroprotective agents have largely failed...
  52. MSU Parkinson Disease Clincal Center
    John L Goudreau; Fiscal Year: 2013
    ..The goal of the NET-PD is demonstrate efficacy of neuroprotective agents in slowing the progression of Parkinson Disease (PD)...
  53. Kinesia-HS: High Sensitivity System for Facilitating Parkinson's Drug Trials
    DUSTIN ALLEN HELDMAN; Fiscal Year: 2011
    ..PUBLIC HEALTH RELEVANCE: Pharmaceutical companies are placing great emphasis on neuroprotective agents designed to slow the progression of Parkinson's disease...
  54. Novel Adjunctive Therapies for NeuroAIDS
    Harris A Gelbard; Fiscal Year: 2013
    ..Our PPG as configured defines a paradigm for a bench-to-bedside path to adjunctive therapy based on MLK3 inhibition. ..
  55. Mechanisms of Neuroinflammation in HAND
    Norman J Haughey; Fiscal Year: 2013
    ..The findings from this project will lead to a better molecular understanding of neuroimmunity that will aid on the development of a new class of neuroprotective drugs that reduce neuroinflammation by inhibition of nSMase2. ..
  56. Structural MRI marker(s) of Parkinson's Disease's Progression
    Xuemei Huang; Fiscal Year: 2013
    ..The goal of this grant is to establish MRI measurements as such a marker, thereby leading to a better understanding of the cause of PD and improved assessment of potential neuroprotective agents in PD.
  57. COVALENT FLAVIN COENZYMES IN FLAVOENZYME CATALYSIS
    Dale E Edmondson; Fiscal Year: 2013
    ..The development of highly specific reversible inhibitors show promise as protectants as these enzyme levels increase with aging in the human. ..
  58. The Role of Cdk5 in Stroke
    James A Bibb; Fiscal Year: 2013
    ....
  59. Combination progesterone &vitamin D in treatment of Traumatic Brain Injury
    Donald G Stein; Fiscal Year: 2012
    ..The PIs'current research is seeking even better results by combining PROG with other neuroprotective agents. A logical first step is to examine the conditions that might limit PROG's beneficial effects in a ..
  60. Mechanisms of Neuroprotection in HIV Encephalitis
    Eliezer Masliah; Fiscal Year: 2013
    ..This new direction represents a natural extension from the previous period of funding and provides a new avenue that might lead to the development of a novel class of HIV neuroprotective drugs. ! ..
  61. Muller Cell Role in Retinal Diseases
    Vijay P Sarthy; Fiscal Year: 2010
    ..We propose to examine (1) whether CNTFtreated Muller cells release neuroprotective agents, which act to prevent photoreceptor loss;and (2) to determine gene expression changes induced in microglia ..
  62. Role of NCKX2 in the activation of toxic Zn2+ influx in ischemic neurons
    Lech Kiedrowski; Fiscal Year: 2010
    ..This research may lead to the development of a novel therapy that could be applied prior to CPB surgeries to improve their safety. ..
  63. Non-Invasive Quantitation of Cellular and Biochemical Changes in Hereditary Ataxi
    GULIN OZ; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): Successful application of potential neuroprotective agents will depend on early detection of neurodegenerative diseases...
  64. Neuroprotective Drugs for Spinal Cord Injury
    JEAN WRATHALL; Fiscal Year: 2001
    ..Ionotropic glutamate antagonists, administered acutely after injury showed promise as neuroprotective agents which has not been borne out by clinical trials due to adverse side effects...
  65. Cerebal Ischemia During Anesthesia and Surgery
    Piyush Patel; Fiscal Year: 2004
    ..Anesthetics are logical candidate neuroprotective agents because they reduce excitotoxic injury...
  66. Parkinson's Disease Neuroprotection Clinical Center
    Charles Adler; Fiscal Year: 2005
    ..To this end creating a multi-center study group to run clinical trials of potential neuroprotective agents has been set as a goal of the NIH...
  67. A Novel Neuroprotective Approach for Ischemia
    Zhi Gang Jiang; Fiscal Year: 2007
    ..At the end of the phase II period, we expect to submit an IND application to the FDA to use PAN-811 for the treatment of transient ischemic stroke and initiate phase Ib clinical trials. [unreadable] [unreadable]..
  68. PARAMEDIC FIELD INITIATION OF MAGNESIUM NEUROPROTECTIVE
    Jeffrey Saver; Fiscal Year: 2003
    ..study will demonstrate the feasibility of performing randomized, controlled clinical trials of promising neuroprotective agents in the field...
  69. A HIGH-THROUGHPUT SCREEN FOR ANTI-NECROTIC COMPOUNDS
    DONALD KIRSCH; Fiscal Year: 2006
    ..2) Execute a pilot screen of -3000 highly selected compounds to identify neuroprotective agents. A library of known bioactive compounds, including many currently marketed drugs, will be screened for ..
  70. PARKINSON DISEASE NEUROPROTECTION CLINICAL TRIAL CENTER
    Bala Manyam; Fiscal Year: 2005
    ..abstract_text> ..
  71. Neurotrophin Blood/Brain Barrier Delivery in Ischemia
    William Pardridge; Fiscal Year: 2006
    unreadable] DESCRIPTION (provided by applicant): Neurotrophins are powerful neuroprotective agents in global or regional brain ischemia when the protein is injected directly into the ischemic brain...